FGF19
FGF19 (Fibroblast growth factor 19) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma and Ovarian cancer.
Overview
Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. Activity requires the presence of KLB and FGFR4.
CIViC holds 5 clinical evidence items and 0 assertions across 4 variants, naming Sorafenib, FGFR4 Inhibitor H3B-6527 and Fisogatinib.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · FGF19 (Fibroblast growth factor 19) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma and Ovarian cancer.
- 1 · What it is
FGF19 (Fibroblast growth factor 19) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma and Ovarian cancer.
- 2 · What goes wrong in cancer
Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes.
- 3 · How drugs use it
No product in this corpus aims at FGF19 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:3675 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O95750 (protein name, function text, keywords and locations (REST API)); CIViC gene FGF19 (5 evidence items, 0 assertions, 4 variants; diseases: Hepatocellular Carcinoma, Ovarian Cancer (GraphQL API, CC0))
Biology
Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. Activity requires the presence of KLB and FGFR4. Location: Secreted (UniProt). Locus 11q13.3 (HGNC).
- Hepatocellular carcinoma: CIViC evidence names this disease
- Ovarian cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 3 therapies; CIViC holds 5 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"FGF19" OR ABSTRACT:"FGF19" OR TITLE:"fibroblast growth factor 19" OR ABSTRACT:"fibroblast growth factor 19" OR TITLE:"Fibroblast growth factor 19" OR ABSTRACT:"Fibroblast growth factor 19") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FGF19, not a curated reading list.